Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Metro, Giulio ^a   Valtorta, Emanuele ^b   Siggillino, Annamaria ^a   Lauricella, Calogero ^b   Cenci, Matteo ^a   Ludovini, Vienna ^a   Minenza, Elisa ^c   Prosperi, Enrico ^d   Ricciuti, Biagio ^a   Rebonato, Alberto ^e   Bassetti, Alessandra ^f   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c S MARIA HOSPITAL   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Narni Hospital   (Italy)

Author keywords

DNA sequencing; Enteric type adenocarcinoma; Gene mutation; KRAS; Non small cell lung cancer

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; K RAS PROTEIN; PARAFFIN; PEMETREXED;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CERVICAL LYMPHADENOPATHY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DNA EXTRACTION; ESOPHAGOGASTRODUODENOSCOPY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; LUNG ADENOCARCINOMA; LUNG LESION; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOLOGY; PAIN SEVERITY; PATHOLOGIST; POINT MUTATION; POLYMERASE CHAIN REACTION; PULMONARY ENTERIC TYPE ADENOCARCINOMA; SEQUENCE ANALYSIS; SMOKING; VERTEBRAL CANAL;

EID: 84938911391     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.559     Document Type: Article

References (18)

1. Platz A et al (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site Mol Oncol 1 395-405 DOI: 10.1016/j.molonc.2007.12.003
2. Stephen AG et al (2012) Dragging ras back in the ring Cancer Cell 25 272-281 DOI: 10.1016/j.ccr.2014.02.017
3. Prior IA, Lewis PD and Mattos C (2012) A comprehensive survey of Ras mutations in cancer Cancer Res 72 2457-2467 DOI: 10.1158/0008-5472.CAN-11-2612 PMID: 22589270 PMCID: 3354961
4. Dearden S et al (2013) Mutation incidence and coincidence in nonsmall-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Ann Oncol 24 2371-2376 DOI: 10.1093/annonc/mdt205 PMID: 23723294 PMCID: 3755331
5. Ludovini V et al (2012) Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations Cancer Chemother Pharmacol 69 1289-1299 DOI: 10.1007/s00280-012-1829-7 PMID: 22302407
6. Smith G et al (2010) Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine Br J Cancer 102 693-703 DOI: 10.1038/sj.bjc.6605534 PMID: 20147967 PMCID: 2837563
7. Bardelli A et al (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Discov 3 658-673 DOI: 10.1158/2159-8290.CD-12-0558 PMID: 23729478 PMCID: 4078408
8. COSMIC - Catalogue of somatic mutations in cancer Available at: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ [accessed 1.1.15]
9. Tsukuda K et al (2000) A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma Biochem Biophys Res Commun 278 653-658 DOI: 10.1006/bbrc.2000.3839 PMID: 11095964
10. Janakiraman M et al (2010) Genomic and biological characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 5901-5911 DOI: 10.1158/0008-5472.CAN-10-0192 PMID: 20570890 PMCID: 2943514
11. Meng D et al (2013) Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis Lung Cancer 81 1-10 DOI: 10.1016/j.lungcan.2013.03.019 PMID: 23608713
12. Metro G et al (2014) Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status Clin Lung Cancer 15 86-92 DOI: 10.1016/j.cllc.2013.08.002
13. Mao C et al (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 272-278 DOI: 10.1016/j.lungcan.2009.11.020
14. Metro G et al (2012) Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype Lung Cancer 78 81-86 DOI: 10.1016/j.lungcan.2012.06.005 PMID: 22770374
15. Sasaki H et al (2011) Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer J Thorac Oncol 6 15-20 DOI: 10.1097/JTO.0b013e31820594f0
16. Chiosea SI et al (2012) KRAS mutant allele-specific imbalance in lung adenocarcinoma Mod Pathol 24 1571-1577 DOI: 10.1038/modpathol.2011.109
17. Jänne PA et al (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 38-47 DOI: 10.1016/S1470-2045(12)70489-8
18. Blumenschein GR et al (2013) MEK114653: a randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC) J Clin Oncol 31(suppl) abstract 8029